Get started
RHYTHM PHARMAC. DL-,001RHYTHM PHARMAC. DL-,001RHYTHM PHARMAC. DL-,001

RHYTHM PHARMAC. DL-,001

No trades
See on Supercharts
Overview
Financials News Ideas Forecast

1RV chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪2.04 B‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.2EUR
Net income (FY)
‪−167.32 M‬EUR
Revenue (FY)
‪70.15 M‬EUR
Shares float
‪54.50 M‬
Beta (1Y)
2.11

About Rhythm Pharmaceuticals, Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
David P. Meeker
Website
rhythmtx.com
Headquarters
Boston
Employees (FY)
226
Founded
2008
FIGI
BBG00HY3NMB2
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange RHYTHM PHARMAC. DL-,001 stocks are traded under the ticker 1RV.
We've gathered analysts' opinions on RHYTHM PHARMAC. DL-,001 future price: according to them, 1RV price has a max estimate of 73.49 EUR and a min estimate of 39.07 EUR. Watch 1RV chart and read a more detailed RHYTHM PHARMAC. DL-,001 stock forecast: see what analysts think of RHYTHM PHARMAC. DL-,001 and suggest that you do with its stocks.
1RV reached its all-time high on Feb 13, 2024 with the price of 48.2 EUR, and its all-time low was 2.8 EUR and was reached on May 19, 2022. View more price dynamics on 1RV chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track RHYTHM PHARMAC. DL-,001 financials in yearly and quarterly reports right on TradingView.
RHYTHM PHARMAC. DL-,001 is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
1RV earnings for the last quarter are −2.18 EUR per share, whereas the estimation was −2.18 EUR resulting in a 0.27% surprise. The estimated earnings for the next quarter are −0.66 EUR per share. See more details about RHYTHM PHARMAC. DL-,001 earnings.
RHYTHM PHARMAC. DL-,001 revenue for the last quarter amounts to ‪24.07 M‬ EUR despite the estimated figure of ‪24.93 M‬ EUR. In the next quarter revenue is expected to reach ‪27.04 M‬ EUR.
1RV net income for the last quarter is ‪−131.02 M‬ EUR, while the quarter before that showed ‪−37.71 M‬ EUR of net income which accounts for −247.45% change. Track more RHYTHM PHARMAC. DL-,001 financial stats to get the full picture.
No, 1RV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 31, 2024, the company has 226.00 employees. See our rating of the largest employees — is RHYTHM PHARMAC. DL-,001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. RHYTHM PHARMAC. DL-,001 EBITDA is ‪−250.05 M‬ EUR, and current EBITDA margin is −235.83%. See more stats in RHYTHM PHARMAC. DL-,001 financial statements.
Like other stocks, 1RV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade RHYTHM PHARMAC. DL-,001 stock right from TradingView charts — choose your broker and connect to your account.